Neuropathy treatment

The three categories

When you next see an advertisement, place it in a column before you place it in your basket. Almost all of them belong in column two while being sold from column one.

Treating the cause

This is the only intervention with good evidence for changing the trajectory of the disease rather than the experience of it.

If your neuropathy is diabetic, glucose control is the treatment, and nothing else on this page competes with it. It is unglamorous, it is slow, and it is the answer. If your neuropathy has another cause — B12 deficiency, thyroid disease, alcohol, an excess of vitamin B6 from a supplement, a medication — then correcting that cause is where recovery, if there is any to be had, comes from.

The corollary is uncomfortable: if nobody has established your cause, no treatment can be aimed at it. A neuropathy evaluation that stopped at “it is probably age” is an unfinished evaluation. The tests worth asking about are listed here.

How much does glucose control actually deliver?

It is worth being precise here, because the honest answer differs by diabetes type and almost nobody says so. A Cochrane systematic review of 17 randomised trials found that intensive glucose control clearly reduces the development of clinical neuropathy in type 1 diabetes — an annualised risk difference of about −1.8%. In type 2 diabetes the same analysis found a smaller effect on clinical neuropathy that did not reach statistical significance (about −0.6%, p = 0.06), although nerve conduction and vibration threshold measures did improve. Intensive control also significantly increased severe hypoglycaemic episodes.

So: if you have type 1, tight control is one of the few genuinely disease-modifying things available to you. If you have type 2 — which is most people reading this — glucose control remains worth doing for every other reason, but expecting it alone to reverse established neuropathy sets you up for disappointment, and the wider metabolic picture of weight, triglycerides, blood pressure and activity appears to carry more of the load than glucose alone. That is not a reason to do less. It is a reason to start the foot protection further down this page now, rather than waiting for the A1c to fix it.

Prescription medicines for nerve pain

Nerve pain does not respond well to ordinary painkillers. Paracetamol and anti-inflammatories, which work on tissue injury, do very little for a pain signal generated by the nerve itself. The medicines that help are ones that act on nerve signalling, and most of them were originally developed for something else.

Broadly, the classes a clinician chooses among are:

• Gabapentinoids — pregabalin and gabapentin. Pregabalin carries a specific approval for painful diabetic peripheral neuropathy; gabapentin is very widely used for the same purpose. Drowsiness, dizziness and swelling are the usual reasons people stop.
• SNRI antidepressants — duloxetine is approved for diabetic peripheral neuropathic pain and is used at doses chosen for pain, not for mood. Being offered an antidepressant for a foot problem surprises people; it is not a comment on whether the pain is real.
• Tricyclic antidepressants — amitriptyline and nortriptyline, usually at low doses at night. Long-established, effective for some people, and limited by dry mouth, grogginess and cautions in older adults and in heart disease.
• Topicals — lidocaine patches, and capsaicin. High-concentration capsaicin applied in a clinic setting has an approval for diabetic neuropathy of the feet; over-the-counter capsaicin creams are far weaker and take weeks of consistent use. What creams can and cannot reach is covered here.

Two points about this list matter more than the list itself. First, professional guidance generally advises against opioids as an ongoing treatment for neuropathic pain, on a balance of modest benefit against substantial harm. Second, a realistic response is a meaningful reduction in pain, not its abolition — and trying a second option after the first disappoints is normal practice rather than failure.

What the guideline actually says about choosing between them

The American Academy of Neurology updated its practice guideline on painful diabetic polyneuropathy in 2022 after a systematic review of the trial literature. It put standardised effect sizes on the classes, and they land closer together than the way they are prescribed would suggest:

Three consequences follow, and they are the most useful things on this page to take to an appointment.

Gabapentin is not the best of these; it is the most prescribed. The guideline tells clinicians to weigh factors other than efficacy — your other conditions, the side effects you can tolerate, cost, interactions — precisely because the classes perform comparably.

If a drug fails, the recommended move is to switch class, not to keep raising the dose. Many people conclude that nothing works for them after a single inadequate trial of one drug. Ask specifically for an agent from a different class.

Opioids are recommended against. The guideline is explicit that clinicians should not use opioids for painful diabetic neuropathy; across a condition lasting years, the risks outrun the benefit.

One expectation to set: an effect size near 0.5 means meaningful improvement for a substantial minority, not relief for everyone. A drug that takes pain from 7/10 to 4/10 and gives you your sleep back is a success. Anything promising to eliminate it is selling.

Sources for this section: Price R, Smith D, Franklin G, et al. Oral and Topical Treatment of Painful Diabetic Polyneuropathy: Practice Guideline Update Summary. Neurology. 2022;98(1):31–43. doi:10.1212/WNL.0000000000013038 · Callaghan BC, Little AA, Feldman EL, Hughes RAC. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database of Systematic Reviews. 2012;(6):CD007543. doi:10.1002/14651858.CD007543.pub2

Physical therapy, balance and movement

Underrated, and one of the few interventions that addresses something medicine does not: the loss of position sense that makes people unsteady and leads to falls. Gait and balance training, strengthening, and — where the front of the foot is weak — a brace to prevent tripping are all concrete, and a referral costs nothing to ask about. Movement also supports glucose control, which puts it back in the first column.

The supplement question

Two supplements come up constantly. Alpha-lipoic acid has the most respectable evidence of any supplement here, and the evidence is still mixed, with the strongest studies using intravenous dosing not available in a bottle. B vitamins help genuinely and substantially when there is a deficiency to correct, and do nothing when there is not — while high-dose B6 in “nerve support” blends can actively cause the problem. The full assessment, including how to read a label for B6, is here.

Devices and procedures

A tier of treatment exists between a prescription and an operation, and it is where the marketing is heaviest.

TENS units are inexpensive, low-risk and have mixed evidence. Reasonable to try; not something to expect much of.

Infrared and low-level light devices are widely sold for neuropathy. The evidence has not persuaded major payers, and where a treatment is not covered after review, that is usually a statement about the evidence rather than about the paperwork.

Spinal cord stimulation is a genuine and quite different case: an implanted device, studied in randomised trials for painful diabetic neuropathy that has not responded to medication, with real reported benefit in that specific refractory group. It is a serious intervention for a serious problem, not a first step.

Surgical nerve decompression for generalised diabetic neuropathy remains contested and is not standard care. Decompression for a nerve genuinely trapped at one point — a different problem with a different pattern — is a different discussion.

How to evaluate a neuropathy clinic package

Clinics selling multi-thousand-dollar neuropathy programs, usually not covered by insurance and usually paid up front, are now common. Some are staffed by conscientious people. The package structure itself is what deserves scrutiny, and five questions do most of the work.

What no treatment replaces

Whatever you take, wear or undergo, the thing that prevents the outcome people fear is not in any of the categories above and costs nothing. Look at your feet every day, in good light, including between the toes and the soles. A foot that cannot feel cannot raise the alarm, so your eyes take over that job. The routine takes about a minute.

When treatment is not the question — be seen promptly

Some things should not wait for the next routine appointment, and this is the part a foot specialist worries about more than the pain. Be seen the same week for an open sore, blister, crack or callus with drainage; redness, warmth or swelling in one foot; a foul smell; or a wound that has not begun to heal within a week. Be seen urgently for a fever alongside any foot wound, for sudden weakness, or for numbness climbing rapidly up the legs. If you have diabetes, treat any foot wound as urgent no matter how small it looks — the ones that end badly rarely looked dramatic at the start.

Common questions

Related reading

Neuropathy in the feet: the full picture · Supplements, honestly assessed · Creams for nerve pain · Home remedies · What makes neuropathy worse · The daily foot check